The high cost and human toll of multidrug-resistant organisms (MDROs)

Multidrug-resistant organisms (MDROs) pose a critical threat to global health, fueling healthcare-associated infections (HAIs), escalating treatment costs, and putting patient safety at risk. This white paper explores the human and economic burden of antimicrobial resistance (AMR), highlights high-risk pathogens such as MRSA and Acinetobacter baumannii, and examines the challenges of limited treatment options. Discover how advanced diagnostic tools, antimicrobial stewardship strategies, and innovative therapies are transforming the fight against MDROs to protect patients and strengthen healthcare systems worldwide.